Annals of Oncology 15:751-758, 2004
© 2004 European Society for Medical Oncology
Original Paper |
A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial
Received 29 September 2003; revised 13 January 2004; accepted 15 January 2004Background:
To compare the efficacy of continuous infusional 5-fluorouracil (5-FU)-based chemotherapy against conventional bolus chemotherapy in the preoperative treatment of patients with large operable early breast cancer.
Patients and methods:
Four hundred and twenty-six women with histologically proven ³3 cm invasive early breast cancer were randomised to receive pre-operative infusional 5-FU 200 mg/m2 by daily 24 h continuous infusion via a Hickman line for 18 weeks with epirubicin 60 mg/m2 intravenous (i.v.) bolus on day 1 and cisplatin 60 mg/m2 i.v. bolus on day 1, both repeating 3-weekly (infusional ECisF), or conventional bolus doxorubicin 60 mg/m2 i.v. on day 1 and cyclophosphamide 600 mg/m2 i.v. on day 1, both repeating 3-weekly (AC), both schedules for six courses. Patients subsequently had local therapy (surgery or radiotherapy or both) and tamoxifen 20 mg orally daily as appropriate.
Results:
The 5 year results for AC and infusional ECisF, respectively, were as follows: overall response, 75% and 77%; complete clinical remission, 31% and 34%; pathological complete remission (pathCR), 16% for both; and pathCR with residual ductal carcinoma in situ (DCIS), 25% and 24%. Mastectomy rates were 37% and 34%, respectively. Five-year overall survival was 74% for AC and 82% for infusional ECisF (hazard ratio 0.76, 95% confidence interval 0.51–1.13; P = 0.18). Both treatments were well tolerated. Grade III/IV lethargy, vomiting, alopecia and plantar-palmar erythema were significantly greater for infusional ECisF; grade III/IV leucopenia was significantly greater for AC.
Conclusions:
Preoperative continuous infusional 5-FU-based chemotherapy is no more active than conventional AC for early breast cancer; with a median 5 year follow-up, the infusion-based schedule shows a non-significant trend towards improved survival.
1 Royal Marsden Hospital; 2 Institute of Cancer Research, London and Sutton; 3 Christie Hospital, Manchester; 4 Mayday University Hospital, Croydon; 5 Royal Bournemouth Hospital; 6 Kent Oncology Centre, Maidstone; 7 St George’s Hospital, London; 8 Addenbrooke’s Hospital, Cambridge; 9 Southend Hospital, Southend-on-Sea; 10 Essex County Hospital, Colchester; 11 Bristol Oncology Centre, Bristol; 12 St James Hospital, Leeds; 13 St Luke’s Cancer Centre, Guildford, UK
Key words: breast neoplasm, chemotherapy, cisplatin, infusional 5-FU, neo-adjuvant, phase III
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Sirohi, M. Arnedos, S. Popat, S. Ashley, A. Nerurkar, G. Walsh, S. Johnston, and I. E. Smith Platinum-based chemotherapy in triple-negative breast cancer Ann. Onc., November 1, 2008; 19(11): 1847 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Berruti, M. P. Brizzi, D. Generali, M. Ardine, L. Dogliotti, P. Bruzzi, and A. Bottini Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions Oncologist, November 1, 2008; 13(11): 1137 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Yen-Revollo, R. M. Goldberg, and H. L. McLeod Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines? Clin. Cancer Res., January 1, 2008; 14(1): 8 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. W. Moon, S. Y. Rha, H. C. Jeung, W. I. Yang, C. O. Suh, and H. C. Chung Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis Ann. Onc., November 1, 2005; 16(11): 1778 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Pagani, C. Sessa, F. Nole, E. Munzone, D. Crivellari, D. Lombardi, B. Thurlimann, D. Hess, R. Graffeo, M. Ruggeri, et al. Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer Ann. Onc., October 1, 2005; 16(10): 1609 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bonnefoi 'Small' randomised neo-adjuvant chemotherapy trials in breast cancer reporting on pathological response: more harm than good? Ann. Onc., September 1, 2005; 16(9): 1407 - 1410. [Full Text] [PDF]
|
|
|
|
|
|
S. Chua, I. E. Smith, R. P. A'Hern, G. A. Coombes, T. F. Hickish, A. C. Robinson, R. W. Laing, M. E. R. O'Brien, S. R. Ebbs, A. Hong, et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2) Ann. Onc., September 1, 2005; 16(9): 1435 - 1441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.R. J. Evans, A. Yellowlees, E. Foster, H. Earl, D. A. Cameron, A. W. Hutcheon, R. E. Coleman, T. Perren, C. J. Gallagher, M. Quigley, et al. Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study J. Clin. Oncol., May 1, 2005; 23(13): 2988 - 2995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Spadaro, E. Ambrosino, M. Iezzi, E. Di Carlo, P. Sacchetti, C. Curcio, A. Amici, W.-Z. Wei, P. Musiani, P.-L. Lollini, et al. Cure of Mammary Carcinomas in Her-2 Transgenic Mice through Sequential Stimulation of Innate (Neoadjuvant Interleukin-12) and Adaptive (DNA Vaccine Electroporation) Immunity Clin. Cancer Res., March 1, 2005; 11(5): 1941 - 1952. [Abstract] [Full Text] [PDF]
|
|